RP-HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-04. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Standard peptides synthesized from amino acids labeled with stable isotope atoms serve as internal standards for serial dilutions of a sample. These allow for later absolute quantification of proteins and post-translational modifications by mass spectrometry. This technique has been adapted to absolute quantification of proteases, deciphering both activity states and total amounts in biological samples. This is thanks to trypsin treatment for mass spectrometry generating peptides specific to inactive zymogen precursors, active proteases, or common to both forms. PSPs is one form of standard peptide for absolute quantification and Standard of the Expressed Protease (STEP) is the other. The major difference between the two is PSP sequences are designed to mimic tryptic peptides that contain sequences spanning the zymogen's pro-domain and the protease's final form, whereas STEP sequences match tryptic peptide sequences found in both forms of the protease. This capitalizes on protease activation, where the zymogen's pro-domain is cleaved off and the final form lacks that domain. Experiments using iTRAQ labeling and LC-MS/MS with STEP and PSP peptide internal standards have successfully quantified total and active protease levels in biological samples. One major drawback for this approach is the inability to account for inhibitor bound enzymes. It is also difficult to ensure standard peptides can be generated for this method for each and every protease for study.
Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour. Common side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended. Famotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2023, it was the 33rd most commonly prescribed medication in the United States, with more than 16 million prescriptions.
=== Books === Wadden, Thomas A.; Van Itallie, Theodore B. (1992). Treatment of the Seriously Obese Patient. Guilford Press. Stunkard, Albert J.; Wadden, Thomas A. (1993). Obesity: Theory and Therapy (2nd ed.). Raven Press. Brownell, Kelly D.; Wadden, Thomas A. (1998). The LEARN Program for Weight Control: Special Medication Edition. American Health Publishing. Wadden, Thomas A.; Stunkard, Albert J. (2002). Handbook of Obesity Treatment. Guilford Press. Wadden, Thomas A.; Bray, George A. (2018). Handbook of Obesity Treatment (2nd ed.). Guilford Press.
=== Water filtration === Given the water adsorption properties of silica gel, it is used in domestic water filters. The surface structure of silica gel allows the adsorption of some minerals that are dissolved in the water, or "ion exchange" as it is marketed. Due to the lack of regulations for domestic water filtration products, no studies validate the manufacturer claims regarding the effectiveness of the filtration system.
To model schizophrenia, animals were injected with phencyclidine (PCP) and, therefore, exhibited symptoms of the disorder, such as social withdrawal and motor responses. Upon injection with ZJ43, these behaviors were decreased, suggesting that an increase in NAAG in the synapse — and its subsequent activation of mGluR3 receptors — has potential as a co-therapy for schizophrenia. In these cases, NAAG peptidase inhibition reduces the adverse effects in these disorders. Future research focuses on the role of NAAG in pain perception, brain injury, and schizophrenia while developing NAAG peptidase inhibitors with even greater ability to cross the blood–brain barrier.[16][17]
Sources: en.wikipedia.org
The ability of the medium to swell in liquid is based on the cross-linking of these substances, the pH and the ion concentrations of the buffers used. Incorporation of high temperature and pressure allows a significant increase in the efficiency of ion chromatography, along with a decrease in time. Temperature has an influence of selectivity due to its effects on retention properties. The retention factor (k = (tRg − tMg)/(tMg − text)) increases with temperature for small ions, and the opposite trend is observed for larger ions. Despite ion selectivity in different mediums, further research is being done to perform ion exchange chromatography through the range of 40–175 °C. An appropriate solvent can be chosen based on observations of how column particles behave in a solvent. Using an optical microscope, one can easily distinguish a desirable dispersed state of slurry from aggregated particles.
Such systems may use taxonomic thesauri to track accepted names and synonyms and to keep checklists aligned with changing taxonomy. Hardisty and colleagues have proposed the concept of "digital extended specimens" as an infrastructure for linking biodiversity records derived from physical specimens to a broader network of related digital objects and third-party data resources. Digitization improves access to specimen data, but it cannot by itself resolve cryptic diversity, which often requires direct examination and sequencing of preserved material. Despite these advances, many regions, particularly in the tropics, still lag behind in collecting and digitizing fungal diversity.
==== Insulin pump ==== An insulin pump delivers insulin subcutaneously. The insulin pump body itself can also contain the algorithm used in an AID system, or it can connect via Bluetooth with a separate mobile device (such as a phone) to send data and receive commands to adjust insulin delivery. Algorithm The algorithm for each AID system differs. In commercial systems (see below), little is known about the details of how the control algorithm works. In open source systems, the code and algorithm are openly available. In general, all algorithms do the same basic functionality of taking in CGM data and based on predicted glucose level's and the user's personal settings (for basal rates, insulin sensitivity, and carbohydrate ratio, for example) then recommends insulin dosing to help bring or maintain glucose levels in target range. Depending on the system, users may have the ability to adjust the target for the system, and may have different settings to ask the system to give more or less insulin in general.
This mating can cause bi-daily surges of prolactin which would normally occur in rodent pregnancy. Prolactin surges initiate the secretion of progesterone which maintains pregnancy and hence can initiate pseudopregnancy. The false maintenance of pregnancy exhibits the outward physical symptoms of pregnancy, in the absence of a foetus. Prolactin receptor activation is essential for normal mammary gland development during puberty in mice. Adult virgin female prolactin receptor knockout mice have much smaller and less developed mammary glands than their wild-type counterparts. Prolactin and prolactin receptor signaling are also essential for maturation of the mammary glands during pregnancy in mice.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.